Related news:Sun Pharma, Reliance Industries: Top stock recommendations for today - Sun Pharma profit up 28% on higher sales - SC upholds NPPA's Rs 4.6 crore penalty on Sun Pharma - Niche drugs: Sun Pharma clocks $1bn sales in FY24 - Sun Pharma Q3 net profit rises 16.5 per cent to Rs 2,523.8 crore - Sun Pharma, Lupin recall drugs in US on manufacturing woes
Sun Pharma Advanced Research Company
Bookmark
ShareSun Pharma Advanced Research Company is a company. It is located in Mumbai, India. The company is part of the Health Care sector, specifically in the Pharmaceuticals industry.
Key facts
- city: Mumbai
- country: India
- sector: Health Care
- industry: Pharmaceuticals
- CEO: Anilkumar Raghavan
- CEO gender: Male
Classified as: organization
Business
Sun Pharma Advanced Research Company is one of the companies in India, companies in Pharmaceuticals, companies in Health Care and 3,550,070 companies in our database.
- Assets: 35.4M $
- Debt: 10M $
- Employees:
Try Pro to see estimates
- Free cash flow: -23230200 $
- Market cap: 759.2M $
- Revenues: 17.3M $
Stocks from Sun Pharma Advanced Research Company:
Talking Points:
- sparc.life
- Sun Pharma Advanced Research Company Ltd. (SPARC) is focused on improving standards of care for patients globally through innovation in therapeutics
- Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, and dermatology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders; and HitGen Ltd. to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited
Learn more about talking points
